A first-in-human phase 1 study of the SHP2 inhibitor BBP-398 in patients with advanced solid tumors.

Falchook G, Braganca Xavier C, Van Veenhuyzen D, Malhotra J, Sadeghi S, Kalebasty AR, Wood L, Rahman F, Li E, Pak Y, Khalil M, Spira AI, Sommerhalder D, Garrido-Laguna I, Hong DS

Open source

DOI
10.1038/s41698-026-01340-1
Published
2026 Feb 28
Container
NPJ precision oncology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1038/s41698-026-01340-1,
  title = {A first-in-human phase 1 study of the SHP2 inhibitor BBP-398 in patients with advanced solid tumors.},
  author = {Falchook G and Braganca Xavier C and Van Veenhuyzen D and Malhotra J and Sadeghi S and Kalebasty AR and Wood L and Rahman F and Li E and Pak Y and Khalil M and Spira AI and Sommerhalder D and Garrido-Laguna I and Hong DS},
  year = {2026},
  journal = {NPJ precision oncology},
  doi = {10.1038/s41698-026-01340-1},
  url = {https://doi.org/10.1038/s41698-026-01340-1}
}

RIS

TY  - JOUR
TI  - A first-in-human phase 1 study of the SHP2 inhibitor BBP-398 in patients with advanced solid tumors.
AU  - Falchook G
AU  - Braganca Xavier C
AU  - Van Veenhuyzen D
AU  - Malhotra J
AU  - Sadeghi S
AU  - Kalebasty AR
AU  - Wood L
AU  - Rahman F
AU  - Li E
AU  - Pak Y
AU  - Khalil M
AU  - Spira AI
AU  - Sommerhalder D
AU  - Garrido-Laguna I
AU  - Hong DS
PY  - 2026
JO  - NPJ precision oncology
DO  - 10.1038/s41698-026-01340-1
UR  - https://doi.org/10.1038/s41698-026-01340-1
ER  - 

APA

G, F., C, B. X., D, V. V., J, M., S, S., AR, K., L, W., F, R., E, L., Y, P., M, K., AI, S., D, S., I, G., & DS, H. (2026). A first-in-human phase 1 study of the SHP2 inhibitor BBP-398 in patients with advanced solid tumors.. NPJ precision oncology. https://doi.org/10.1038/s41698-026-01340-1

Source records